Connors Investor Services Inc. Grows Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Connors Investor Services Inc. increased its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 58.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Connors Investor Services Inc. owned about 0.05% of Organogenesis worth $193,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ORGO. Acadian Asset Management LLC increased its position in shares of Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock valued at $8,521,000 after acquiring an additional 471,741 shares during the period. GSA Capital Partners LLP increased its position in shares of Organogenesis by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 531,218 shares of the company’s stock valued at $1,509,000 after acquiring an additional 269,315 shares during the period. Los Angeles Capital Management LLC increased its position in shares of Organogenesis by 45.9% in the 1st quarter. Los Angeles Capital Management LLC now owns 500,567 shares of the company’s stock valued at $1,422,000 after acquiring an additional 157,575 shares during the period. BNP Paribas Financial Markets increased its position in shares of Organogenesis by 573.9% in the 1st quarter. BNP Paribas Financial Markets now owns 123,386 shares of the company’s stock valued at $350,000 after acquiring an additional 105,078 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Organogenesis in the 1st quarter valued at $207,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Performance

NASDAQ:ORGO traded up $0.11 during mid-day trading on Monday, hitting $3.01. The company’s stock had a trading volume of 122,542 shares, compared to its average volume of 971,343. Organogenesis Holdings Inc. has a 1 year low of $1.96 and a 1 year high of $4.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.41. The stock has a market cap of $399.04 million, a price-to-earnings ratio of 75.27 and a beta of 1.64. The business’s fifty day moving average is $2.72 and its two-hundred day moving average is $3.01.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Organogenesis had a net margin of 1.34% and a return on equity of 2.11%. The business had revenue of $109.98 million for the quarter, compared to analyst estimates of $100.44 million. During the same period in the prior year, the company posted ($0.02) EPS. Analysts anticipate that Organogenesis Holdings Inc. will post -0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Lake Street Capital assumed coverage on shares of Organogenesis in a report on Friday, June 28th. They issued a “buy” rating and a $5.00 price target on the stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.